top
Please input keywords
About Biocytogen
Biocytogen (stock code:02315.HK) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMab/RenLite mice platforms for fully human monoclonal and bispecific antibody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process.
More
Our Pipeline
With our new drug development system that encompasses the entire R&D process, we specialize in immunotherapy and have established numerous research pipelines in cancer, autoimmune diseases, metabolic diseases, and infectious diseases. Our unwavering commitment is to deliver effective and safe antibody drugs to patients while tackling global health challenges collaboratively.
More
Our Technologies
Our proprietary RenMice platform, which includes RenMab, RenLite and RenNano, has enabled us to develop a comprehensive antibody drug discovery platforms. These include fully human monoclonal antibodies, bispecific antibodies, nanobodies, bispecific ADCs (antibody-drug conjugates), GPCR antibodies and TCR-mimic antibodies. Our cutting-edge platforms enable us to efficiently develop innovative antibody drugs in large-scale.
More
Newly Reached Collaborations
BEIJING, March 8, 2023 -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") (HKEX: 02315), today announced the signing of a non-exclusive license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (“Janssen”). Under the agreement, Biocytogen grants Janssen and its affiliates a non-exclusive worldwide license to use Biocytogen’s proprietary RenLite® platform and underlying intellectual property to discover, research, develop, manufacture and commercialize fully human antibody therapeutics with a common light chain and other biological therapeutics for an unlimited number of drug targets and indications. The agreement was facilitated by Johnson & Johnson Innovation LLC. RenLite is a member of Biocytogen's fully human antibody RenMiceTM family. RenLite mice can generate fully human antibody candidates with high specificity, affinity, diversity and good druggability, with a common light chain for subsequent assembly of bispecific and multispecific antibodies with a low mismatch and high success rate. The bispecific and multispecific antibodies assembled after RenLite discovery have a traditional antibody structure and exhibit ideal physiochemical properties that are advantageous for downstream CMC development. Dr. Yuelei Shen, Founder, Chairman and CEO of Biocytogen, said: “We are pleased to partner with Janssen to accelerate the discovery of new antibody-based drugs for patients.” About RenMiceTM RenMiceTM are Biocytogen’s proprietary genetically modified mice that generate antibodies with fully human variable domains. The models, which include RenMabTM, RenLite® and RenNano® mouse platforms, as well as substrains containing additional modifications, were developed using Biocytogen’s size-unlimited, precise chromosome engineering technology (SUPCE), which allows for in situ replacement of the murine immunoglobulin genes with their human counterpart. All RenMice platforms contain the entire human heavy chain VDJ loci, with the RenMab mouse harboring all human light chain VJ loci. In contrast, the RenLite mouse contains a single human VJ locus in situ to facilitate future bispecific antibody assembly, while the RenNano mouse has modified heavy chain constant regions to generate functional heavy-chain-only antibodies (HCAbs). RenMice can generate robust immune response and produce fully human antibodies with great diversity, specificity, affinity and druggability. The development of RenMice has allowed Biocytogen to launch 6 fully human antibody discovery platforms: monoclonal antibody (RenMab), bispecific antibody and bispecific ADC (RenLite), nanobody (RenNano), TCR-mimic antibody for intracellular targets (HLA/RenMice, i.e., MHC humanized RenMice), and a RenMice HiTS (hyperimmune target specific) antibody platform designed for GPCR and other challenging targets. As of June 30, 2022, RenMice have been licensed by 16 biopharmaceutical companies around the world, including Merck KGaA, Xencor, BeiGene, and Innovent. About Biocytogen Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM/RenLite®/RenNano® mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, respectively, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. As of June 30, 2022, this project has resulted in 28 drug co-development agreements and 16 RenMiceTM licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's internal pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn. Biocytogen’s Contacts Antibody platforms and antibody assets: BD-Licensing@biocytogen.com Media: pr@bbctg.com.cn
2023.03.08
BEIJING, China, February 27th, 2023 - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that its wholly owned subsidiary, Eucure (Beijing) Biopharma Co., Ltd. (“Eucure Biopharma”), has reached an exclusive licensing agreement with Chipscreen NewWay Biosciences (“Chipscreen NewWay”), a holding subsidiary of Shenzhen Chipscreen Biosciences Co., Ltd. (“Chipscreen Biosciences”, SSE: 688321) for the clinical development and commercialization of bispecific antibody YH008 in Greater China (including Mainland China, Hong Kong, Macau and Taiwan). Eucure Biopharma retains YH008’s global rights to develop and commercialize YH008 outside Greater China. Under the agreement, Chipscreen NewWay will pay Eucure Biopharma an upfront payment of 40 million RMB, a potential development milestone payment of up to 360 million RMB, a potential sales milestone payment of up to 196 million RMB, as well as tiered royalties on net sales. YH008 is Biocytogen’s independently developed proprietary bispecific antibody for tumor immunotherapy. The IND application for a phase I study of YH008 was cleared by the US FDA and accepted by the Chinese NMPA. “Chipscreen Biosciences and Chipscreen NewWay have extensive experience in clinical drug development and commercialization,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “With this agreement in place, we will work together to accelerate YH008’s entry into the market to benefit patients.” “Biocytogen’s YH008 has unique mechanisms and outstanding precllinical results,” said Dr. Xianping Lu, CEO and President of Chipscreen Biosciences. “This licensing agreement will expand Chipscreen NewWay’s pipeline in the field of antibody drugs and immuno-oncology. I look forward to these fruitful collaborations.” “The unique mechanism of action of YH008 bring together the synergies of immune activation and immunosuppressive blockade, and can reduce toxic side effects and increase safety,” said Dr. Bin Liu, Head of the Center of Antibody Early R&D at Chipscreen NewWay. “The clinical potential of YH008 is worth looking forward to and it is a good addition to the products under development of Chipscreen NewWay. Chipscreen NewWay will rapidly advance the clinical stage research and development of YH008.” About YH008 YH008 is a bispecific antibody that exerts antagonistic and agonistic activities. In vitro and in vivo studies indicate that YH008 can conditionally activate the immune pathway in the tumor microenvironment where certain tumor specific T cells are enriched to avoid systemic non-specific activation. Additionally, YH008 was engineered with an Fc-silent IgG1 isotype to avoid Fc-receptor-mediated non-specific immune activation. YH008 demonstrated superior anti-tumor activity when compared to parental monoclonal antibodies (mAbs) or combination therapy in syngeneic models. In vivo pharmacodynamic studies indicate that YH008 can activate tumor-infiltrating DCs and T cells. In addition, both in vivo studies and GLP toxicology studies indicate improved safety of YH008 compared with benchmark mAbs. About Eucure Biopharma As a wholly owned subsidiary of Biocytogen, Eucure Biopharma undertakes the mission of clinical development for Biocytogen’s R&D pipelines. Relying on a strong clinical development team and extensive clinical development experience, Eucure Biopharma focuses on antibody drug therapy for oncology and other indications. The company has established a product pipeline for more than 10 targets, with two products in launched phase II multi-regional clinical trials (MRCT) and two in phase I. For details, please visit https://www.eucure.com/en/index. About Biocytogen Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM/RenLite®/RenNano® mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. As of June 30, 2022, this project has resulted in 28 drug co-development agreements and 16 RenMiceTM licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn. About Chipscreen In 2001, Chipscreen Biosciences was founded in Shenzhen, specializing in the research and development of original small molecule drugs. With the self-created "integrated drug discovery and early evaluation platform based on chemical genetics" as its core competitiveness, Chipscreen Biosciences has now become one of China's leading innovative drug enterprises, forming a modern biomedicine group company in Shenzhen, as its headquarters / research and development center / GMP production base, Chengdu, as a regional headquarter / research and development center / GMP production base, Beijing clinical research center and Shanghai commercial center. At present, the company has developed a number of original new drug product lines for tumors, diabetes, and endocrine and autoimmune diseases. In December 2014, the original anti-tumor new drug Chidamide was approved by the China Food and Drug Administration for marketing. Shenzhen Chipscreen Biosciences Co., Ltd. (Stock symbol: 688321.SH) has been listed on the SSE STAR Market on August 12, 2019. About Chipscreen NewWay Biosciences Chipscreen NewWay, affiliated with Chipscreen, is an innovative and R&D-driven biotech company dedicated to developing large molecules and other novel therapeutic modalities, including antibodies/ADC-centered large molecules, and nucleic acid drugs. It develops innovative drugs that meet clinical needs and novel mechanisms of action in multiple therapeutic areas such as oncology and autoimmunity while providing patients with innovative mechanisms and globally leading-based new therapeutic approaches and options. Chipscreen NewWay has built a large molecular R&D center of over 1,800 square meters in Chengdu Hi-Tech Zone and has established an experienced antibody and ADC R&D team from the discovery to the early process development, with a number of in-house and cooperation projects in continuous and rapid advancements. Biocytogen's Contacts Antibody drug assets and platforms: BD-Licensing@biocytogen.com Media: pr@bbctg.com.cn
2023.02.27
News
More
31
May , 2023
Biocytogen Opens San Francisco Office to Accelerate Globalization
Beijing, China and San Francisco, CA, May 31, 2023 - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) has announced the opening of a new office in San Francisco, California, USA. The new space will aim to accelerate the globalization of Biocytogen’s businesses. San Francisco is renowned as a hub of the biotechnology industry, and is home to several renowned biopharmaceutical companies. In addition, the proximity of world-class universities facilitates the transformation of academic discoveries into life-saving therapies. Biocytogen’s new West Coast office will position the company to establish and deepen collaborations with the development and licensing of new therapeutic antibodies derived from Project Integrum, as well as use of the company’s preclinical contract research services and animal models by academic and industrial clients. Dr. Yuelei Shen, Founder, Chairman and CEO of Biocytogen, said: “The opening of the San Francisco office will strengthen our global business development and accelerate the realization of our vision – to become a global headstream of new drugs. We look forward to advancing the development of innovative drugs with partners around the world to benefit patients.” Reference 1. Adapted from https://en.wikipedia.org/wiki/Oyster_Point_Marina/Park About Biocytogen Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM/RenLite®/RenNano® mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum (RenMiceTM HiTS Platform). As of December 31, 2022, 34 therapeutic antibody development/out-licensing/transfer agreements and 17 RenMiceTM licensing agreements have been established worldwide, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's pipeline is comprised of 11 core assets, with partnerships established for 4 out of 6 total clinical assets. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn. Biocytogen Contacts Antibody platform and assets: BD-Licensing@biocytogen.com Preclinical models and services: info@bbctg.com.cn Media: pr@bbctg.com.cn San Francisco Office Address: Biocytogen 611 Gateway Blvd Ste 120, South San Francisco, CA 94080
24
May , 2023
Biocytogen to Present Pipeline Assets and R&D Progress at BIO International Convention, June 5-8, 2023
Biocytogen’s antibody BD and licensing (BDL) team will be delivering an oral presentation on Monday, June 5th at the 2023 BIO International Convention in Boston, taking place from June 5-8. The presentation will highlight Biocytogen’s clinical and preclinical pipeline assets, 6 fully human antibody discovery platforms, as well as the progress of Project Integrum, an initiative to develop therapeutic antibodies for more than 1000+ targets. Biocytogen’s BDL team will also host one-on-one partnering meetings at the event. MEET WITH US Using Biocytogen’s proprietary fully human antibody RenMiceTM, Biocytogen has built 6 antibody discovery platforms: monoclonal antibody (mAb) platform: RenMabTM-based monoclonal antibody discovery with high affinity and great diversity; bispecific antibody (BsAb) platform: RenLite®-based common light chain bispecific antibody discovery with high pairing success rate and good druggability; bispecific ADC (BsADC) platform: high-throughput RenLite®-based bispecific ADC discovery for 200+ TAA targets with good tumor specificity, anti-tumor activity, and CMC efficiency; nanobody platform: RenNano®-based single-domain antibody (nanobody) discovery with great blood-brain-barrier permeability and tumor infiltrating ability, suitable for the assembly of bispecific, multi-specific antibodies, CAR-T therapies, etc. TCR-mimic antibody platform: HLA-transgenic RenMice-based TCR-mimic (TCRm) antibody divscovery for intracellular targets with superior affinity and specificity; GPCR platform: target knockout RenMice-based antibody discovery for multi-species cross-recognition of GPCR and other challenging targets; With an established in vivo efficacy screening platform and streamlined antibody development capability, Biocytogen launched Project Integrum to develop therapeutic antibodies for more than 1000+ targets. Since the initiation of Project Integrum, the company has generated 6 clinical stage assets: YH003: CD40 mAb, which is currently in phase II MCRTs; YH001: CTLA-4 mAb in an ongoing phase I clinical trial in partnership with TRACON for the treatment of sarcoma; YH008: PD-1 × CD40 BsAb, which has received FDA and NMPA IND clearance, has been licensed in Greater China by Chipscreen NewWay Biosciences; YH002: OX40 mAb, which is in phase I clinical trials in Australia and China; YH004: 4-1BB mAb, which is in phase I clinical trials in Australia and China; YH005: Claudin 18.2 mAb which has been out-licensed to RemeGen to develop Claudin 18.2 ADC, known as RC118. and numerous preclinical stage assets: 10+ fully human bispecific antibodies, including YH006 (CTLA-4 x OX40 BsAb); 20+ bispecific antibody-drug conjugates, including YH012 (HER2 x TROP2 BsADC), YH013 (EGFR x MET BsADC) and BSA01 (EGFR x MUC1 BsADC); 10+ TCR-mimic antibodies targeting intracellular TAAs, including WT-1, KRAS, P53, AFP, GP100 and NY-ESO-1; 80+ monoclonal antibodies targeting B7H3, TNFR2, CCR8, AMHR2 and other novel TAAs, co-stimulatory/co-inhibitory molecules, tumor microenvironment molecules, GPCRs, and other popular targets; 600+ antibody hits for oncology, inflammatory/autoimmune disease targets, infectious disease targets, and neurodegenerative disease targets, including B7H4, DLL3, MUC1, GPRC5D, PSMA, LRRC15, GUCY2C, LILRB2, NECTIN-4, ROR1, TIGIT and others. Biocytogen’s antibody assets and RenMice platforms have been recognized by many pharmaceutical and biotech companies. As of December 31, 2022, Biocytogen has reached 34 preclinical antibody co-development or licensing agreements with 21 companies, including Merck KGaA, ADC Therapeutics, Hansoh Pharma, Chipscreen NewWay, LiberoThera, RemeGen, China Resources Biopharm and Nanjing Chia-Tai Tianqing Pharmaceutical Company (NJCTTQ). Additionally, the company has licensed RenMice (RenMab/RenLite) to 17 companies, including Merck KGaA, Janssen, BeiGene, Xencor and Innovent; 40 projects have initiated. The team is looking forward to discussing licensing and co-development opportunities with you, either for antibody assets or fully human antibody discovery platforms. To schedule 1-on-1 partnering meetings, please visit https://www.bio.org/events/bio-international-convention/one-one-partneringtm. For questions, or more information, please contact BD-Licensing@biocytogen.com.
18
May , 2023
Meet Biocytogen’s APAC Business Development Team at 70th JALAS 2023!
Biocytogen’s Asia-Pacific business development team is pleased to exhibit at the 70th Japanese Association for Laboratory Animal Science (JALAS) annual meeting from May 24-26, 2023 in Tsukuba, Japan! Join us at Booth D-3 to learn more about how BioMice models and services, our fully human antibody discovery platforms and antibody assets can help you develop antibody-based therapeutics!   Schedule a Meeting with us   BioMice is Biocytogen’s sub-brand that provides preclinical contract research services and products, including custom and off-the-shelf animal and cell models and preclinical pharmacology evaluation services, including in vivo/ex vivo efficacy, MOA, PK/PD, pilot toxicity studies and in vitro cell-based assays for antibody-related drug MOA/efficacy/safety evaluation. Specifically, BioMice has genetically engineered 800+ animal and cell models to support drug discovery and research, including 530+ target humanized mice and 100+ target humanized cell lines for in vivo efficacy and safety evaluation of anti-human antibodies.  In addition, BioMice offers 770+ strains of KO mice for target validation and 30+ immunodeficient mouse/rat models for CDX, PDX studies. For example, the B-NDG B2M KO plus model shows a reduced GvHD response after PBMC reconstitution, and thus can significantly prolong the experimental window; B-NDG hIL15 mice can promote human NK cell differentiation and can be used for NK cell-based therapeutic efficacy studies.  If you want to generate a new gene-edited model, BioMice offers a gene editing platform (ESC/HR, CRISPR based EGE) for KI, KO, cKI, CKO mouse/rat model generation. 9 out of the Top 10 global MNCs and 7 out of the Top 10 Japanese pharmaceutical companies use BioMice models and/or CRO services. For a full list of BioMice products/publications, and CRO services, visit www.biomice.com. Using Biocytogen’s proprietary fully human antibody RenMice, Biocytogen has built 6 antibody discovery platforms: monoclonal antibody (RenMabTM), bispecific antibody and bispecific ADC (RenLite®), nanobody (RenNano®), TCR-mimic antibody for intracellular targets (HLA/RenMice, i.e., MHC humanized RenMice), and our RenMice HiTS (hyperimmune target specific) antibody platform designed for GPCR and other challenging targets. With our streamlined antibody development capability, Biocytogen launched Project Integrum, an initiative to develop therapeutic antibodies for more than 1000+ targets. Since the initiation of Project Integrum, the company has generated 6 clinical stage assets and numerous preclinical stage assets (10+ fully human bispecific antibodies, 20+ bispecific antibody-drug conjugates, 10+ TCR-mimic antibodies, 80+ monoclonal antibodies, and 600+ antibody hits). Whether you’re interested in our BioMice models, antibody discovery platforms, or our therapeutic antibody assets, we look forward to exploring collaboration opportunities with you at the event!   Schedule a Meeting with us   For questions, please contact info@bbctg.com.cn. About Biocytogen Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM/RenLite®/RenNano® mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum (RenMiceTM HiTS Platform). As of December 31, 2022, 34 therapeutic antibody development/out-licensing/transfer agreements and 17 RenMiceTM licensing agreements have been established worldwide, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's pipeline is comprised of 11 core assets, with partnerships established for 4 out of 6 total clinical assets. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn.